<DOC>
	<DOCNO>NCT01204307</DOCNO>
	<brief_summary>To compare differential influence 1st line doublet chemotherapy contain Docetaxel versus Pemetrexed clinical efficacy Erlotinib second line therapy patient relapse progressed non-squamous NSCLC .</brief_summary>
	<brief_title>Influence Prior Chemotherapy Clinical Benefit With Erlotinib Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Without EGFR Gene Mutation</brief_title>
	<detailed_description>The clinical management advance non-small cell lung cancer ( NSCLC ) remain challenge . Initial therapy advance NSCLC platinum-based regimen show consistent overall response rate 30 % 40 % progression-free interval 4-5 month 1-year survival rate 35 % 40 % [ 1-3 ] . First line doublet chemotherapy commonly use daily practice include Gemcitabine , vinorelbine , paclitaxel docetaxel proven efficacy platinum best supportive care , prolong survival approximately 3 month . Recently , pemetrexed , multi-target antifolate agent , introduce 1st line doublet chemotherapy platinum-based regimen similar efficacy well safety profile compare docetaxel gemcitabine [ 4 ] . Although agent seem equivalent efficacy , tolerability tends concern docetoxel . Myelosuppression standard docetaxel schedule 75 mg/m2 administer every 3 week extremely frequent severe ; neutropenia occur 54 % 67 % patient febrile neutropenia occur 1.8 % 8.0 % patient [ 5 , 6 ] . Moreover , non-hematologic toxicity , grade 3-4 asthenia ( 12 % 18 % ) , nausea vomiting ( 1 % 3.6 % ) , uncommon [ 5 , 6 ] . To increase tolerability docetaxel , alternative schedule extensively study . Accumulating evidence suggest weekly schedule docetaxel ( 35 mg/m2 ) reduce severe febrile neutropenia without decrease antitumor activity [ 7-10 ] . Nevertheless , significant difference observe anemia , thrombocytopenia , non-hematologic toxicity [ 7 ] . For reason , low dose docetaxel ( 60 mg/m2 every 3 week ) recommend Japan [ 11 , 12 ] . However , recent large scale trial dose docetaxel still reveal high incidence grade 3 4 neutropenia ( 82.9 % ) [ 12-14 ] . Different schedule low dose docetaxel study , comparison make low dose docetaxel less toxic agent , pemetrexed . Currently , investigator follow schedule weekly low dose docetaxel ( 30 mg/m2 day 1 8 every 3 week ; 60 mg/m2 accumulate dose cycle ) hospital effort achieve good tolerability ( press-chemotherapy 2010 ) . The investigator therefore perform exploratory study , prospective analysis , investigate efficacy toxicity low dose docetaxel schedule compare pemetrexed patient NSCLC chemotherapy naive . Erlotinib , orally-available epidermal growth factor receptor ( EGFR ) tyrosine-kinase inhibitor ( TKI ) , significantly prolongs survival produce significant symptom quality-of-life benefit compare best supportive care unselected patient relapse non-small-cell lung cancer ( NSCLC ) [ 15 , 16 ] . In large , phase III , placebo-controlled study ( BR.21 ) , erlotinib produce survival benefit across patient sub-groups study [ 15 ] .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Patients &gt; 18 year , &lt; 75 year old 2 . Pathological confirmation nonsquamous NSCLC 3 . Clinical stage IIIB IV 4 . Measurable tumor size RECIST criterion 5 . ECOG &lt; 2 6 . Adequate hematological laboratory parameter 7 . Adequate hepatic , renal laboratory parameter 1 . Unspecified NSCLC 2 . Prior therapy chemotherapy EGFR TKI monoclonal antibody 3 . Any unstable systemic disease ( active infection , hypertension , unstable angina , CHF , liver cirrhosis , end stage renal failure etc. , ) 4 . Nursing pregnant mother 5 . Untreated Brain metastasis 6 . ECOG &gt; 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>